Dimethazine

Synopsis

Dimethazine (Mebolazine): A Comprehensive Encyclopedic Reference

1. Identity and Chemical Characterization

Names and Nomenclature

Mebolazine — bearing the International Nonproprietary Name (INN) mebolazine and formerly sold under the brand names Dostalon and Roxilon — is also widely known as dimethazine, dymethazine, di(methasterone) azine, or by the systematic chemical name 2α,17α-dimethyl-5α-androstan-17β-ol-3-one azine. Additional historical synonyms documented in chemical reference databases include Diarethyl, Dimetazin, Dimetina, and the research abbreviation DMZ. Its molecular formula is C₄₂H₆₈N₂O₂, with a molecular weight of approximately 633.0 g/mol, and it carries the CAS Registry Number 3625-07-8.

Chemical Classification and Structure

Dimethazine is a synthetic, orally active androgen/anabolic steroid (AAS) and a 17α-alkylated derivative of dihydrotestosterone (DHT) which is no longer marketed. What sets it apart structurally from all other common anabolic steroids is its dimeric architecture. It has a unique and unusual chemical structure, being a dimer of methasterone linked at the 3-position of the A-ring by an azine group, and reportedly acts as a prodrug of methasterone. An azine group is a nitrogen–nitrogen double-bond linkage (–C=N–N=C–) formed between two ketone-bearing steroids. Because the parent molecule is composed of two methasterone units bridged by this nitrogen bond, it carries a combined molecular mass approximately double that of methasterone alone. It is classified as a C17-alkylated anabolic-androgenic steroid that exhibits similar effects to Superdrol (methasterone/methasteron).

Physical Form and Common Preparations

Dimethazine appears as an off-white solid under standard laboratory conditions. In the dietary supplement trade it has been sold in oral capsule and tablet form, typically packaged alongside other designer steroids. It is catalogued by reference-standard suppliers under the product categories of hormones, steroids and derivatives, and reference materials for sports drugs and steroid testing. As an orally active compound, no parenteral pharmaceutical formulations are documented in the scientific literature.

2. Origins, Development, and Historical Context

Synthetic Origin

Dimethazine has no botanical or natural source; it is a fully synthetic compound with no counterpart in the plant kingdom or in endogenous human biochemistry. It is a man-made anabolic-androgenic steroid that was initially created and researched in Italy in the 1960s. Its first documented appearance in the scientific literature dates to 1962, when Italian researchers published what is now the foundational biological assessment of the compound.

Early Italian Research (1960s)

'DMZ' was first studied in Italy in the 1960s for its potent anabolic effects, employed for a variety of indications including gynecologic malignancy, osteoporosis, fibrocystic dysplasia, tuberculosis, and cachexia in children (Matscher et al., 1962; De Ruggieri et al., 1963). The 1962 study by Matscher, Lupo, and De Ruggieri, published in Bollettino della Società italiana di biologia sperimentale, specifically examined the biological activity of dimethazine in the protein anabolic sense, published in October 1962. In animal studies, dimethazine was found to have a greater myotrophic effect than methyltestosterone, oxymetholone (Anadrol), and testosterone propionate (Matscher et al., 1962; De Ruggieri et al., 1963). Despite this promising early pharmacological profile, the compound did not achieve lasting clinical adoption and was eventually withdrawn from pharmaceutical markets.

Traditional Medical Context

It is important to note that dimethazine has no traditional or ethnobotanical history of use; it is a mid-20th century synthetic pharmaceutical compound. Its early "traditional" use was therefore strictly within the context of 1960s Italian clinical investigation. Originally developed in the mid-20th century, dimethazine was researched for its potential medicinal benefits, particularly in the context of muscle-wasting diseases and conditions requiring improved recovery and tissue repair. The indications explored during this period — tuberculosis, osteoporosis, gynecological cancer, pediatric cachexia — reflected the broader 1960s interest in anabolic steroids as general restorative agents, a clinical paradigm that subsequently fell from favor as safety concerns about this drug class accumulated.

Re-emergence as a Dietary Supplement (2008 onward)

Since 2008, mebolazine has been used illegally as an ingredient in some dietary supplements, including vitamin B supplements, and in the United States the Food and Drug Administration has taken legal action against such manufacturers. The supplement industry marketed products containing dimethazine under brand names such as "Super DMZ Rx," "Xtreme DMZ," and "Dymethazine," targeting bodybuilders and strength athletes. Designer anabolic steroids have been popular for over a decade as a way to achieve classic anabolic steroid-like results from products sold in the legal marketplace.

3. Active Compounds and Mechanism of Action

Prodrug Relationship with Methasterone

The primary biochemical identity of dimethazine lies in its role as a prodrug. It is recognized as a prodrug that is metabolized in vivo to its active form, methasterone, a potent agonist of the androgen receptor. The azine bond linking the two methasterone units is susceptible to hydrolysis under physiological conditions. The product 'Xtreme DMZ' contains the designer steroid dimethazine (DMZ), which consists of two methasterone molecules linked by an azine group; in a stability study, degradation from dimethazine to methasterone was observed.

Metabolic Profile

The metabolism of dimethazine has been characterized using human liver microsomes and an in vivo chimeric mouse model. In a study using human liver microsomes and a uPA⁺/⁺-SCID chimeric mouse model to elucidate the metabolism of a steroid product called 'Xtreme DMZ,' which contains dimethazine (DMZ), consisting of two methasterone molecules linked by an azine group, degradation from dimethazine to methasterone was observed. By a combination of LC-HRMS and GC-MS(/MS) analysis, methasterone and six other dimethazine metabolites (M1–M6), which are all methasterone metabolites, could be detected alongside the parent compound in both models. The phase-II metabolism of dimethazine was also investigated in mouse urine samples; only metabolites M1 and M2 were exclusively detected in the glucuro-conjugated fraction, while all other compounds were also found in the free fraction. The practical doping-control implication of this metabolic cascade is that for effective control of dimethazine misuse in doping control samples, screening for methasterone and methasterone metabolites should be sufficient.

Androgen Receptor Mechanism

Once hydrolyzed to methasterone, dimethazine's active metabolite engages the classical genomic androgen receptor pathway. Mebolazine, a derivative of dihydrotestosterone (DHT) and prodrug of methasterone, exerts its anabolic activity primarily through its interaction with the androgen receptor (AR), a ligand-activated transcription factor. The sequence of intracellular events comprises several steps: in the cytoplasm, methasterone binds to the ligand-binding domain of the androgen receptor, causing a conformational change and dissociation of heat shock proteins; the activated methasterone-AR complex then translocates into the nucleus, where it dimerizes and binds to specific DNA sequences known as Androgen Response Elements (AREs) in the promoter regions of target genes; this binding recruits co-activator proteins and initiates the transcription of genes responsible for anabolic effects such as increased protein synthesis in muscle tissue.

Because methasterone is a derivative of 5α-dihydrotestosterone, it cannot be aromatized to estrogens, nor is it subject to 5α-reductase further reduction — meaning it does not convert to more potent androgenic metabolites in androgen-sensitive peripheral tissues in the same manner as testosterone.

4. Scientific Evidence by Area of Use

4.1 Anabolic / Muscle-Building Effects

Animal evidence (1960s): The only experimental data specifically examining dimethazine's anabolic properties originates from preclinical Italian research in the 1960s. In animal studies, dimethazine was found to have a greater myotrophic effect than methyltestosterone, oxymetholone (Anadrol), and testosterone propionate. These studies used standard rodent bioassay models (levator ani / seminal vesicle assays) to measure anabolic versus androgenic potency. The published reports arising from this work indicate a notable tissue-selectivity toward muscle over androgen-sensitive secondary sexual structures, though the preclinical methods of that era had significant limitations.

Human / clinical evidence: There are no published randomized controlled trials, cohort studies, or systematic reviews in humans evaluating dimethazine as a standalone intervention for muscle hypertrophy, strength, or body composition. Ethical objections restrict the use of designer steroids in human administration studies. The clinical case report literature (discussed under Safety) documents use by individual bodybuilders but does not contain controlled outcome data. The complete absence of human efficacy trials means that any purported muscle-building benefit in humans is extrapolated from animal data and from the pharmacology of its active metabolite, methasterone — extrapolation that carries significant uncertainty.

Evidence strength: Very weak — limited to animal studies from the 1960s; no controlled human trials exist.

4.2 Applications Investigated in 1960s Clinical Research

The range of conditions investigated by Italian researchers in the 1960s — gynecologic malignancy, osteoporosis, fibrocystic dysplasia, tuberculosis, and cachexia in children — reflects the permissive investigational environment of that era rather than established therapeutic indications. No results from these investigations have been replicated, extended, or incorporated into any contemporary clinical guideline or regulatory approval. The compound was withdrawn from pharmaceutical markets and none of the original indications achieved approved therapeutic status.

Evidence strength: Historical only; not reproducible or applicable to modern evidence standards.

4.3 Anti-Doping Detection Research

The most rigorous peer-reviewed research involving dimethazine concerns not its clinical effects but its forensic detection in doping control. The 2016 study by Geldof and colleagues (Geldof L, Tudela E, Lootens L, et al., Biomed Chromatogr. 2016;30(8):1202–9) used human liver microsomes and an in vivo humanized mouse model to fully characterize the metabolic conversion of dimethazine to methasterone and six methasterone metabolites. This work established that by a combination of LC-High Resolution Mass Spectrometry (HRMS) and GC-MS(/MS) analysis, methasterone and six other dimethazine metabolites (M1–M6) were identified; the use of anabolic steroids is prohibited in sports, and effective control is done by monitoring their metabolites in urine samples collected from athletes. This body of work is methodologically robust within the anti-doping analytical chemistry domain.

5. Body Systems and Health Areas Associated with Dimethazine

5.1 Musculoskeletal System

The primary pharmacological target is skeletal muscle. Through activation of AREs in myocytes, the active metabolite methasterone promotes transcription of genes involved in protein synthesis and nitrogen retention — the classical androgenic-anabolic axis. However, as noted above, human efficacy data are absent.

5.2 Hepatic System

The liver is the organ most directly implicated in documented harm from dimethazine. As a 17α-alkylated AAS, it is associated with drug-induced hepatotoxicity. Methylstenbolone and dymethazine are androgenic anabolic steroids gaining popularity among bodybuilders for their performance-enhancing properties; they are found together in Super DMZ Rx 2.0, a "dietary supplement" for bodybuilders; the first case of Super DMZ Rx 2.0-induced cholestatic jaundice involved a 26-year-old previously healthy Caucasian male who took the supplement according to the manufacturer's instructions for 30 days. It is important for physicians to be aware of this while considering causes of jaundice, since AAS-induced liver injury can become fulminant.

5.3 Endocrine and Reproductive System

Like all exogenous androgens, dimethazine (through its active metabolite) activates the androgen receptor systemically. This produces negative feedback on the hypothalamic–pituitary–gonadal (HPG) axis. Recent evidence suggests that anabolic steroid use may be the most common cause of hypogonadism in men of reproductive age. Severe side effects including hepatotoxicity, cholestasis, renal failure, hypogonadism, gynecomastia, and infertility have been reported secondary to the use of designer AAS products. Because methasterone (the active metabolite) does not aromatize to estrogen, estrogenic side effects such as gynecomastia are considered pharmacologically unlikely with dimethazine specifically, though the absence of aromatization does not eliminate HPG suppression or virilizing effects.

5.4 Cardiovascular System

Like exogenous androgens, designer steroids have the potential to cause reversible adverse effects such as hypertension, secondary hypogonadism, infertility, as well as polycythemia and adverse changes in lipoprotein subfractions. Adverse lipoprotein changes — particularly suppression of HDL-cholesterol and elevation of LDL-cholesterol — are a class effect of 17α-alkylated oral anabolic steroids, though no cardiovascular-outcomes data specific to dimethazine exist in the published literature.

5.5 Dermatological and Androgenic Peripheral Tissues

Dimethazine, as a DHT derivative, acts directly on androgen receptors in skin and the scalp without requiring 5α-reductase conversion. Anabolic steroids such as dymethazine might cause side effects including infertility, behavioral changes, hair loss, and acne. Prostate tissue similarly expresses androgen receptors and is a potential target of androgenic stimulation, though no human prostate-outcome studies for dimethazine specifically have been published.

6. Dosage Forms and Reported Dosages

Dimethazine has no approved pharmaceutical dosage; the compound was withdrawn from pharmaceutical use and never received modern regulatory approval for any indication.

In the context of the documented case report, dymethazine was associated with cholestasis in a healthy patient who took 1 capsule of the "supplement" twice daily for 30 days. The specific milligram content per capsule of the implicated supplement (Super DMZ Rx 2.0) is not described in the published peer-reviewed case report.

Ethical objections restrict the use of designer steroids in human administration studies; to overcome these problems, alternative in vitro and in vivo models were developed to identify metabolites and to assure a fast response by anti-doping laboratories, using human liver microsomes and a uPA⁺/⁺-SCID chimeric mouse model. No dose-ranging, pharmacokinetic, or dose–response studies in humans have been published in peer-reviewed literature.

7. Regulatory and Legal Status

United States

In the U.S., it is illegal to include anabolic steroids in supplement products. On December 18, 2014, the Designer Anabolic Steroid Control Act of 2014 (DASCA) became law, amending the Controlled Substances Act (CSA) to expand the list of scheduled anabolic steroids. DASCA gives the DEA additional authority to identify and quickly respond when new designer anabolic steroids — illegal drugs — are falsely marketed as dietary supplements. Since 2010, when the FDA announced a crackdown on anabolic steroids in dietary supplements, the FDA has issued more than 80 warning letters, consumer advisories, and product recalls for products found to illegally contain anabolic steroids. The FDA has taken specific legal action against manufacturers who included mebolazine in products. Since 2008, mebolazine has been used illegally as an ingredient in some dietary supplements, including vitamin B supplements, and in the United States the Food and Drug Administration has taken legal action against such manufacturers.

Anti-Doping Status

These chemicals are also banned by the World Anti-Doping Agency (WADA). Dymethazine is used for weight loss, to improve athletic performance, to reduce sexual problems, and for many other uses, but there is no good scientific evidence to support its use. As an anabolic androgenic steroid, dimethazine falls under WADA's prohibited list in the category of exogenous anabolic androgenic steroids, which are banned in competition and out of competition. Despite recent regulatory efforts that have banned specific compounds, many anabolic-androgenic steroids (AAS) remain available in over-the-counter dietary supplements that are legally sold in the United States.

8. Safety Considerations and Documented Adverse Effects

8.1 Hepatotoxicity — Case Report Evidence

The most well-documented safety signal for dimethazine in humans is cholestatic liver injury. A 2014 case report represents the first known case of cholestatic jaundice in a patient taking Super DMZ Rx 2.0 "nutritional supplement." The case involved a 26-year-old previously healthy male who followed the product's dosing instructions for 30 days. Biopsy findings included essentially normal hepatic architecture at scanning magnification with no significant steatosis, inflammation, or fibrosis, but cholestasis and mild hepatocellular edema were present around the central vein; under oil immersion, pale yellow bile pigment was seen within hepatocyte cytoplasm and also as discrete canalicular bile plugs; the portal tract showed minimal mixed chronic inflammation. The authors of the case report concluded that although the manufacturer of Super DMZ Rx 2.0 did not conceal methylstenbolone and dymethazine as the major ingredients, unregulated AAS use is unsafe, and it is important for physicians to be aware of this while considering causes of jaundice since AAS-induced liver injury can become fulminant.

This case report constitutes a single observation of drug-induced cholestatic jaundice. While cholestatic hepatotoxicity is a recognized class-effect of 17α-alkylated oral anabolic steroids, no systematic epidemiological studies specifically quantifying the incidence of this complication with dimethazine have been published. Its structural similarity to other 17α-alkylated AAS suggests potential risks including liver damage, cardiovascular complications, and hormonal imbalances.

8.2 HPG Axis Suppression and Hypogonadism

Recent evidence suggests that anabolic steroid use may be the most common cause of hypogonadism in men of reproductive age. Exogenous androgen use, by suppressing hypothalamic GnRH secretion and pituitary LH and FSH release, induces secondary (central) hypogonadism that may persist after cessation. Severe side effects including hepatotoxicity, cholestasis, renal failure, hypogonadism, gynecomastia, and infertility have been reported secondary to the use of these products; while some of these side effects may be reversible, more aggressive use may result in more permanent end-organ damage.

8.3 Cardiovascular Risk

Like exogenous androgens, designer steroids have the potential to cause adverse effects such as hypertension, polycythemia, and adverse changes in lipoprotein subfractions. Suppression of HDL cholesterol is a consistent finding with 17α-alkylated oral anabolic steroids as a class. Anabolic steroids such as dymethazine might cause side effects including infertility, behavioral changes, hair loss, and acne; they might also lead to liver damage and heart disease.

8.4 Broader Class-Effect Adverse Profile

Despite recent regulatory efforts that have banned specific compounds, many AAS remain available in over-the-counter dietary supplements that are legally sold in the United States; severe side effects including hepatotoxicity, cholestasis, renal failure, hypogonadism, gynecomastia, and infertility have been reported secondary to the use of these products. The Rahnema et al. 2015 review in Andrology — the primary peer-reviewed synthesis of evidence on designer steroids including dimethazine — concluded that severe side effects have been reported secondary to the use of these products, and while some may be reversible, more aggressive use may result in more permanent end-organ damage.

8.5 Absence of Estrogenic Effects

One pharmacologically verifiable distinction of dimethazine relative to testosterone-based anabolic steroids is the inability of its active metabolite methasterone to undergo aromatization to estradiol. Because the compound is a DHT-derived steroid, it does not serve as a substrate for aromatase. This means estrogenic side effects such as water retention and gynecomastia are pharmacologically not expected through this specific pathway; however, this does not equate to a favorable safety profile, and the androgenic, hepatic, and cardiovascular hazards described above remain applicable.

8.6 Supplement Adulteration Context

Many nutritional supplements rely on androgen precursors to deliver their promises, without adequately informing consumers of the potential side effects; these products may conceal the presence of potent androgens to avoid regulatory sanctions and become more appealing to consumers. The Rahnema et al. (2015) review specifically identified dimethazine as one of six designer steroids whose presence in retail supplement products warranted regulatory scrutiny, noting that a vast number of designer steroids exist, many are novel compounds with no associated published research.

9. Evidence Summary and Scientific Limitations

The totality of peer-reviewed research on dimethazine can be summarized as follows. The foundational biology was established through Italian animal studies in 1962–1963 (Matscher et al.; De Ruggieri et al.), demonstrating a myotrophic effect that exceeded comparator steroids in rodent models. All subsequent scientific literature concerns either: (a) anti-doping analytical chemistry (primarily the Geldof et al., 2016, Biomedical Chromatography study characterizing metabolites); (b) a single peer-reviewed case report documenting cholestatic hepatotoxicity (Agbenyefia et al., 2014, J Investig Med High Impact Case Rep); or (c) systematic reviews of designer steroids as a class (Rahnema et al., 2015, Andrology) that include dimethazine within broader analyses.

There are no randomized controlled trials, no dose-ranging pharmacokinetic studies in humans, no long-term safety studies, and no approved therapeutic indications for dimethazine in any jurisdiction. While detailed experimental data for this compound is limited in publicly available literature, current understanding is consolidated primarily through reference to its structural relationship with methasterone. All claims regarding its performance-enhancing efficacy in humans therefore remain unsubstantiated by controlled evidence.